Workflow
purification and handling
icon
Search documents
Here's Why Qiagen (QGEN) is a Strong Growth Stock
ZACKS· 2025-06-20 14:51
Core Insights - Zacks Premium offers various tools for investors to enhance their stock market strategies, including daily updates, research reports, and stock screens [1][2] - The Zacks Style Scores are designed to help investors select stocks with the highest potential to outperform the market in the short term [2][3] Zacks Style Scores Overview - Stocks are rated from A to F based on value, growth, and momentum, with A being the highest score indicating better chances of outperforming [3] - The Style Scores are categorized into four types: Value Score, Growth Score, Momentum Score, and VGM Score [3][4][5][6] Value Score - Focuses on identifying undervalued stocks using financial ratios such as P/E, PEG, and Price/Sales [3] Growth Score - Concentrates on a company's financial health and future growth potential, analyzing projected and historical earnings, sales, and cash flow [4] Momentum Score - Aims to capitalize on price trends by evaluating recent price changes and earnings estimate revisions [5] VGM Score - Combines all three Style Scores to provide a comprehensive rating, highlighting stocks with attractive value, growth forecasts, and momentum [6] Zacks Rank Integration - The Zacks Rank utilizes earnings estimate revisions to simplify stock selection, with 1 (Strong Buy) stocks historically yielding an average annual return of +25.41% since 1988 [7][8] - Investors are encouraged to select stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B for optimal success [9][10] Company Spotlight: Qiagen (QGEN) - Qiagen N.V. is a leading provider of technologies for nucleic acid handling, with a diverse portfolio of over 500 proprietary products [11] - Qiagen holds a Zacks Rank of 2 (Buy) and a VGM Score of B, with a projected year-over-year earnings growth of 7.3% for the current fiscal year [12] - The company has seen upward revisions in earnings estimates, with a Zacks Consensus Estimate of $2.34 per share, and an average earnings surprise of 4.9% [12][13]
Why Qiagen (QGEN) is a Top Growth Stock for the Long-Term
ZACKS· 2025-06-04 14:50
Core Insights - Zacks Premium offers various tools for investors to enhance their stock market strategies and confidence [1] - The Zacks Style Scores are designed to help investors select stocks with the highest potential to outperform the market in the short term [2] Zacks Style Scores Overview - The Style Scores consist of four categories: Value Score, Growth Score, Momentum Score, and VGM Score, each targeting different investment strategies [3][4][5][6] - Value Score focuses on identifying undervalued stocks using financial ratios [3] - Growth Score assesses a company's future earnings and financial health to find sustainable growth opportunities [4] - Momentum Score capitalizes on price trends and earnings outlook changes to identify favorable buying times [5] - VGM Score combines all three styles to highlight stocks with the best overall potential [6] Zacks Rank and Style Scores Interaction - The Zacks Rank is a proprietary model that uses earnings estimate revisions to simplify portfolio building [7] - Stocks rated 1 (Strong Buy) have historically achieved an average annual return of +25.41% since 1988, significantly outperforming the S&P 500 [8] - To maximize returns, investors should focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B [9] - Stocks with lower ranks (4 or 5) may still have high Style Scores but are likely to face declining earnings forecasts [10] Company Spotlight: Qiagen (QGEN) - Qiagen N.V. is a leading provider of technologies for nucleic acid separation and purification, with a portfolio of over 500 proprietary products [11] - Qiagen holds a Zacks Rank of 2 (Buy) and a VGM Score of A, indicating strong growth potential [12] - The company is forecasted to achieve a year-over-year earnings growth of 6.9% for the current fiscal year, with upward revisions from analysts [12] - Qiagen's average earnings surprise stands at 4.9%, making it a strong candidate for growth investors [12][13]